Kevin Dillon, Cfa
About Kevin Dillon, Cfa
Kevin Dillon, CFA, is the Senior Vice President of Corporate Finance & FP&A at Bristol Myers Squibb, with over 20 years of experience in finance, including roles at Pfizer and Credit Suisse.
Current Position at Bristol Myers Squibb
Kevin Dillon is the Senior Vice President of Corporate Finance & FP&A at Bristol Myers Squibb. In this role, he oversees comprehensive financial planning and analysis. His responsibilities include shaping financial strategies and ensuring robust fiscal health for the company. He is a key figure in the company's finance operations and plays a crucial role in strategic decision-making processes.
Previous Roles at Bristol Myers Squibb
Kevin Dillon has held several significant positions at Bristol Myers Squibb before his current role. From 2022 to 2023, he served as Senior Vice President of CFP&A & Strategic Finance in the New York City Metropolitan Area. Prior to that, he was the Vice President, Finance-Strategic Planning from 2021 to 2022 in Princeton, New Jersey. These roles allowed him to leverage his expertise in strategic financial planning and corporate finance.
Career at Pfizer
Before joining Bristol Myers Squibb, Kevin Dillon worked at Pfizer in various capacities. He was the Vice President, Assistant Treasurer from 2017 to 2021, and Senior Director, Corporate Development from 2013 to 2018. He initially joined Pfizer as Director, Treasury-Capital Markets from 2010 to 2013. During his tenure, he contributed significantly to corporate development and capital market initiatives.
Early Career and Positions
Kevin Dillon began his career at Arthur Andersen & Co. as a Senior Associate in Valuation Services, where he worked from 2001 to 2004. He later moved to KPMG US, where he served as Manager, Economic & Valuation Services from 2005 to 2009. Following this, he spent a year at Credit Suisse as Vice President, Alternative Investments in Greater New York City Area.
Educational Background
Kevin Dillon holds an MBA in Corporate Finance from NYU Stern School of Business, which he obtained between 2007 and 2009. He also has a BA in Economics from Wake Forest University, where he studied from 1997 to 2001. His education has provided a strong foundation for his career in finance and corporate strategy.
Significant Acquisitions Led
Kevin Dillon played a pivotal role in leading the financial strategy for several major acquisitions at Bristol Myers Squibb. These include the $5B acquisition of Mirati, the $14B acquisition of Karuna, and the $4B acquisition of RayzeBio. His expertise in M&A and strategic finance has been instrumental in these high-value transactions.
Operational and Strategic Experience
With over 20 years of experience in finance, Kevin Dillon has a robust background in operational, strategic, and transactional aspects. His experience encompasses international risk management, digital transformation, capital structure management, and M&A/divestitures. He excels in driving cross-functional collaboration and is a trusted business partner across various enterprises.